Search results
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Zacks via Yahoo Finance· 5 days agoAbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop...
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at...
Benzinga· 5 days agoLAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes,
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory...
The Port Lavaca Wave· 6 days ago- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD)
Sam Faiers sparks uproar over ‘dangerous' Crohn's disease claims
Daily Express· 6 days agoTOWIE alum Samantha Faiers was met with backlash from fans as to took to Instagram with a clip from...
Invisible Invaders: How Microplastics Sneak Into Your Brain
SciTechDaily· 5 days agoUniversity of New Mexico researchers have identified that microplastics, once ingested, can migrate...
What Experts Want You to Know Before You Try Colostrum Supplements
Good Housekeeping via Yahoo News· 3 days agoAlso known as "liquid gold," colostrum supplements are going viral on TikTok for having incredible...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation | The Motley Fool
The Motley Fool· 4 days agoThree Motley Fool contributors believe they've identified good picks -- and they're all big biotech...
Can Chemical Agents and Pollens Induce Food Allergies?
Medscape· 6 days agoCan the increasingly present "irritants" in our environment, such as detergents or microplastics,...
Alvotech (NASDAQ:ALVO) Short Interest Update
ETF DAILY NEWS· 5 days agoAlvotech (NASDAQ:ALVO – Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 93,900 shares, a drop ...
AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Zacks· 5 days agoAbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.